For many development teams, the key question is no longer whether IVBE can work, but how early it should be integrated into the program to have a tangible impact on risk, timelines, and cost.

These questions and factors were at the core of a presentation by our Head of Biologics Department, Milan Maděra, delivered to our clients at Conscio Science Day in Munich.

In the PDF document below, we bring you a snapshot that outlines how we approach IVBE for locally acting drug products, from smart analytical design to robust data evaluation aligned with regulatory expectations.

By browsing the slides, you will see:

  • how IVBE can reshape your development roadmap in terms of both timelines and budget,

  • how different in vitro tools can be integrated into a coherent IVBE strategy,

  • why rigorous method development and validation are essential for a successful submission.

All concepts are drawn from our day-to-day work at Quinta-Analytica (a Conscio Group company) and are meant to serve as inspiration and a benchmark for your own development strategy.

Download the IVBE Analytical Tools for Chemical Research PDF


Would you like to know more? Let us know.

Additional News

  • 5 srpna 2025

    Preclinical Bioanalysis That Accelerates Clinical Entry

    How fit-for-purpose and GLP-compliant bioanalysis can streamline your path to IND and CTA approvals.

  • 22 června 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency

  • 15 června 2023

    Novavax & Conscio: Behind the Scenes of Vaccine Development

    Discover how the Conscio Group and renowned vaccine manufacturer Novavax collaborate behind the scenes to ensure quality and efficiency in vaccine production.